Clinical Applications of Cytokines as Inflammation Markers: An Overview

biyomedikalozel5-1-24kapak

Sedef YENİCEa
aGayrettepe Florence Nightingale Hospital, Clinic of Medical Biochemistry, İstanbul, Türkiye

Yenice S. Clinical applications of cytokines as inflammation markers: An overview. In: Koçdor H, Pabuççuoğlu A, Zihnioğlu F, eds. Inflammation and in vitro Diagnostics. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.28-37.

Article Language: EN

ABSTRACT
Inflammation plays a pivotal role in various diseases, and the identification of reliable biomarkers is crucial for diagnostic and therapeutic advancements. Cytokines, as signaling molecules, including interleukins, interferons, tumor necrosis factors, and chemokines, have a variety of pro-inflammatory and anti-inflammatory effects on the body through different biochemical pathways and interactions. These critical mediators, which monitor and regulate immune and inflammatory responses through complex networks, serve as biomarkers for many diseases. Stimuli, actions, interactions, and downstream effects of cytokines have been studied more extensively in recent years, and clinical research has also sought to incorporate cytokines into causal patterns to aid diagnosis and treatment. This review provides an overview of the evolving landscape of cytokines as markers of inflammation and offers insights into their diagnostic precision, prognostic significance, and therapeutic potential in various inflammatory diseases.

Keywords: Cytokine; inflammation; biomarker

Referanslar

  1. Megha KB, Joseph X, Akhil V, Mohanan PV. The cascade of immune mechanism and consequences of inflammatory disorders. Phytomedicine. 2021;91: 153712. [Crossref]  [PubMed]  [PMC]
  2. [cited: December 27]. [Link]
  3. Yong-Jun Liu, et al. TSLP: An Epithelial Cell Cytokine that Regulates T Cell Differentiation by Conditioning Dendritic Cell Maturation.Annu. Rev. Immunol. 2007;25:193-219. [Crossref]  [PubMed]
  4. Mosmann TR, Sad S. The expanding universe of T cell subsets ÐTh1, Th2, and more. Immunol Today. 1996;17:138-46. [Crossref]  [PubMed]
  5. Heijmans-Antonissen C, Wesseldijk F, Munnikes RJ, et al. Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1. Mediators Inflamm. 2006;2006:28398. [Crossref]  [PubMed]  [PMC]
  6. Zurawski G, de Vries JE. Interleukin 13, is an interleukin-4-like cytokine that acts on mono-cytes and B cells, but not on T cells. Immunol Today. 1994; 15:19-26. [Crossref]  [PubMed]
  7. Darif D, Hammi I, Kihel A, El Idrissi Saik I, Guessous F, Akarid K. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb Pathog. 2021;153:104799. [Crossref]  [PubMed]  [PMC]
  8. Charo IF, Romsohoff RM. The many roles of chemokines and chemokines receptors in inflammation. NEJM. 2006;354:610-21. [Crossref]  [PubMed]
  9. Druszczyńska M, Godkowicz M, Kulesza J, Wawrocki S, Fol M. Cytokine Receptors-Regulators of Antimycobacterial Immune Response. Int J Mol Sci. 2022;23(3):1112. [Crossref]  [PubMed]  [PMC]
  10. Xiong K, Li G, Zhang Y, Bao T, Li P, Yang X, et al. Effects of glutamine on plasma protein and inflammation in postoperative patients with colorectal cancer: a meta-analysis of randomized controlled trials. Int J Colorectal Dis. 2023; 38(1):212. [Crossref]  [PubMed]  [PMC]
  11. Queiro R, Aurrecoechea E, Alonso Castro S, Villa Blanco I, Brandy-Garcia A, Linge R. Interleukin-17-targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile. Front Immunol. 2023;14:1203372. [Crossref]  [PubMed]  [PMC]
  12. Graterol Torres F, Molina M, Soler-Majoral J, Romero-González G, Rodríguez Chitiva N, Troya-Saborido M, et al. Evolving Concepts on Inflammatory Biomarkers and Malnutrition in Chronic Kidney Disease. Nutrients. 2022;14(20): 4297. [Crossref]  [PubMed]  [PMC]
  13. Laborde CM, Castro-Santos P, Díaz-Peña R. Contribution of Multiplex Immunoassays to Rheumatoid Arthritis Management: From Biomarker Discovery to Personalized Medicine. J Pers Med. 2020;10(4):202. [Crossref]  [PubMed]  [PMC]
  14. Ulloa L, Tracey KJ. The "cytokine profile": a code for sepsis. Trends Mol Med. 2005;11(2):56-63. [Crossref]  [PubMed]
  15. Molloy RG, Mannick JA, Rodrick ML. Cytokines, sepsis and immunomodulation. Br J Surg. 1993;80(3):289-97. [Crossref]  [PubMed]
  16. Blackwell TS, Christman JW. Sepsis and cytokines: current status. Br J Anaesth. 1996;77(1):110-7. [Crossref]  [PubMed]
  17. Daniel G. Remick, et al. Cytokine Therapeutics for the Treatment of Sepsis: Why Has Nothing Worked? Current Pharmaceutical Design. 2003;9:75-82. [Crossref]  [PubMed]
  18. [cited: December 27]. [Link]
  19. Ansar W, Ghosh S. Inflammation and Inflammatory Diseases, Markers, and Mediators: Role of CRP in Some Inflammatory Diseases. Biology of C Reactive Protein in Health and Disease. 2016:67-107. [Crossref]
  20. Katsanos AH, Kyriakidi K, Karassa FB, Politis D, Skamnelos A, Christodoulou DK, et al. Biomarker Development in Chronic Inflammatory Diseases. Biomarkers for Endometriosis. 2017:41-75. [Crossref]
  21. Bodaghi A, Fattahi N, Ramazani A. Biomarkers: Promising and valuable tools towards diagnosis, prognosis, and treatment of COVID-19 and other diseases. Heliyon. 2023;9(2):e13323. [Crossref]  [PubMed]  [PMC]
  22. Kany S, Vollrath JT, Relja B. Cytokines in Inflammatory Disease. Int J Mol Sci. 2019;20(23):6008. [Crossref]  [PubMed]  [PMC]
  23. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636-43. [Crossref]  [PubMed]  [PMC]
  24. Tsilingiris D, Vallianou NG, Karampela I, Christodoulatos GS, Papavasileiou G, Petropoulou D, et al. Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights into Epidemiology, Pathogenesis, Therapeutic Perspectives, and Challenges. Int J Mol Sci. 2023;24(13):10458. [Crossref]  [PubMed]  [PMC]
  25. Liu QQ, Cheng A, Wang Y, Li H, Hu L, Zhao X, et al. Cytokines and their relationship with the severity and prognosis of coronavirus disease 2019 (COVID-19): a retrospective cohort study. BMJ Open. 2020;10(11):e041471. [Crossref]  [PubMed]  [PMC]
  26. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017;9(6):7204-18. [Crossref]  [PubMed]  [PMC]
  27. Monastero RN, Pentyala S. Cytokines as Biomarkers and Their Respective Clinical Cutoff Levels. Int J Inflam. 2017;2017:4309485. [Crossref]  [PubMed]  [PMC]
  28. Koelman L, Pivovarova-Ramich O, Pfeiffer AFH, Grune T, Aleksandrova K. Cytokines for evaluation of chronic inflammatory status in ageing research: reliability and phenotypic characterisation. Immun Ageing. 2019;16:11. [Crossref]  [PubMed]  [PMC]
  29. Jamaludeen N, Beyer C, Billing U, Vogel K, Brunner-Weinzierl M, Spiliopoulou M. Potential of Point-of-Care and At-Home Assessment of Immune Status via Rapid Cytokine Detection and Questionnaire-Based Anamnesis. Sensors (Basel). 2021;21(15):4960. [Crossref]  [PubMed]  [PMC]
  30. Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G. Cytokines: From Clinical Significance to Quantification. Adv Sci (Weinh). 2021;8(15):e2004433. [Crossref]  [PubMed]  [PMC]
  31. Grimaldi C, Finco D, Fort MM, Gliddon D, Harper K, Helms WS, et al. Cytokine release: A workshop proceedings on the state-of-the-science, current challenges and future directions. Cytokine. 2016;85:101-8. [Crossref]  [PubMed]
  32. Amsen D, de Visser KE, Town T. Approaches to determine the expression of inflammatory cytokines. Methods Mol Biol. 2009;511:107-42. [Crossref]  [PubMed]  [PMC]
  33. Ter Horst R, Jaeger M, Smeekens SP, Oosting M, Swertz MA, Li Y, et al. Host and Environmental Factors Influencing Individual Human Cytokine Responses. Cell. 2016;167(4):1111-24.e13. [Crossref]  [PubMed]  [PMC]
  34. Kupcova Skalnikova H, Cizkova J, Cervenka J, Vodicka P. Advances in Proteomic Techniques for Cytokine Analysis: Focus on Melanoma Research. Int J Mol Sci. 2017;18(12):2697. [Crossref]  [PubMed]  [PMC]